CD137抗體的全球市場:臨床試驗及市場趨勢(2023年)

Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023

出版日期: 2023年04月01日 | 出版商:

KuicK Research | 英文 211 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

本報告提供全球CD137抗體市場相關調查，臨床概要，CD137抗體概要，以及臨床試驗趨勢，及加入此市場的主要企業的競爭情形等資訊。

Global CD137 Antibodies Clinical Trials Insight By Company, Indication & Phase
Insight On More Than 60 CD137 Antibodies In Clinical Trials
Key Antibodies Study Initiation & Expected Completion Year
First Commercially Available CD137 Antibody In Next 6 To 7 Years
Proprietary Technology Platforms By Companies
Orphan Drug Designations & IND Approvals
CD137 Antibodies As Monotherapy & Combination Therapy
Key Funding, Collaboration & Licensing insights
Top 20 Companies Insight By Antibodies In Trials
CD137 Therapeutic Approaches By Monoclonal, Bispecific, Trispecific & Tetraspecific Antibodies

The TNF superfamily, or the tumor necrosis factor superfamily, has garnered a lot of attention lately for the dual role displayed by its members in cancer. TNF can function as both cancer promoters and repressors, which is why the TNF family has gained consideration for its therapeutic promise in the recent years. Likewise, the receptors for these proteins have also been explored for their therapeutic potential, which has been addressed by preventing them from interacting with members of the TNF family. One of the tumor necrosis factor receptors, CD137, has recently attracted interest in the cancer therapeutics domain for its potential spanning several indications altogether. Many pharmaceutical companies are now working to develop antibodies that bind to CD137 that can be used in the treatment of different cancers.

CD137, also known as 4-1BB, was discovered in the late 1980s as a costimulatory protein found on activated CD8+ T cells and NK cells. Further, it was also discovered that the binding of the CD137 with its ligand CD137L enhanced immune response. Because of this important observation, a lot of efforts have been put in to stimulate the activities of the CD137 by developing agonistic antibodies for it. These antibodies have been mostly developed as monoclonal and bispecific antibodies; however, with the ongoing clinical development of trispecific and tetraspecific antibodies, these novel antibody formats have also been incorporated in the clinical pipelines for CD137 antibodies.

Utomilumab and Urelumab were among the first CD137 agonists to be developed and introduced in human clinical trials. They were developed by Bristol-Myers Squibb and Pfizer, both being prominent companies in the pharmaceutical industry, and the involvement of these two companies in the clinical development of CD137 antibodies was a major factor that triggered the entry of more pharmaceutical companies in the CD137 antibodies market. At present, many prominent companies are now developing agonistic antibodies for CD137, which has been beneficial in bringing attention to this novel drug class.

Currently, all candidates in the global clinical trials pipeline are in early phases of clinical evaluation, with the farthest candidates making it to the phase 2. Additionally, a majority of these have been developed for cancer indications, including both solid and hematological cancers. Genmab, Roche, Cullinan Oncology, Sichuan Baili Pharmaceutical, Systimmune and Eutilex are some prominent pharmaceutical companies with antibody assets designed to target and stimulate the CD137.

Sichuan Baili Pharmaceutical and its US-based subsidiary Systimmune, have pioneered the development and clinical evaluation of tetraspecific antibodies, which is evident from their pipelines. All of their tetraspecific antibodies engage the CD137 protein, along with CD3 and PD-L1, apart from a cancer antigen that binds to the fourth binding arm. GNC-03, which has been developed using the companies' proprietary GNC platform, is the only tetraspecific antibody in clinical trials that targets the CD137, and is also the only tetraspecific antibody in phase II of clinical evaluation. It is being assessed for the treatment of leukemia and lymphoma.

Additionally, Pieris Pharmaceuticals has also created waves in the market of CD137 antibodies with its candidate cinrebafusp alfa (PRS-343). PRS-343 is a bispecific fusion protein that targets the CD137 along with the HER2 receptor. The protein acts as an agonist and antagonist for the two receptors respectively, making it one of a kind. It is being tested for patients with gastric cancer expressing HER2.

For the development of a more efficient cancer treatment regimen, many companies have come forward to form collaborations to carry out clinical trials and research activities to enable the development and evaluation of potential drug combinations. For instance, the recent clinical collaboration between Compass Therapeutics and Merck was aimed at this. Compass' CD137 agonist CTX-471 is in phase 1b of clinical evaluation for the treatment of unspecific solid cancers as a monotherapy. However, its collaboration with Merck was focused on evaluating the combination of CTX-471 with the anti-PD-1 blockbuster Keytruda in patietns with metastatic or locally advanced non-small cell lung cancer. The trial dosed the first patient in December 2022 and is currently enrolling more patients.

The therapeutic potential of CD137 has been investigated exhaustively and has now been confirmed as studies from running clinical and research studies emerge. Many companies are now developing agonists against this receptor protein, and within the next five years, the first antibody binding the CD137 is anticipated to gain approval. The market is driven by many factors such as the increasing prevalence of cancer, increasing investment in the cancer therapeutics domain and the involvement of prominent companies. The segment is anticipated to thrive in the coming years as CD137 gains more popularity as a agonistic target.

1. Brief Introduction To CD137

1.1. Clinical Overview
1.2. Biological History Of CD137
1.3. CD137 Hosting An Era Of Agonists Over Antagonists
1.4. Bi-Directional Signaling In CD137

2. CD137 Progression In Autoimmune & Infectious Diseases

2.1. Autoimmune Disorders
2.2. Viral Infections
2.3. Bacterial infections

3. CD137 Antibodies By Cancer & Ongoing Clinical Trials

3.1. Leukemia
3.2. Lymphoma
3.3. Non Small Cell Lung Cancer
3.4. Melanoma
3.5. Breast Cancer
3.6. Colorectal Cancer

4. Global CD137 Antibodies Clinical Trials Overview

4.1. By Company
4.2. By Country
4.3. By Indication
4.4. By Phase
4.5. By Patient Segment

5. Global CD137 Antibodies Clinical Trials Insight By Company, Indication & Phase

5.1. Research
5.2. Preclinical
5.3. Phase-I
5.4. Phase-I/II
5.5. Phase-II

6. CD137 Targeting Proprietary Technology Platforms By Companies

7. CD137 Antibodies Market & Clinical Trends Outlook

7.1. Current Market Trends
7.2. Clinical Stance
7.3. Drug Designations
7.4. Future Market Opportunity Outlook

8. CD137 Therapeutic Approaches By Antibodies Classification

8.1. Monoclonal Antibody Based Strategies
8.2. Bispecific Antibody Centered Approaches
8.3. Trispecific Antibody Established Strategies
8.4. Tetraspecific Antibody Strategies

9. Monotherapy & Combination Therapy With CD137 Antibodies

10. Competitive Landscape

10.1. ABL Bio
10.2. Adagene
10.3. Alligator Bioscience
10.4. BeiGene
10.5. Bicycle Therapeutics
10.6. BioNTech
10.7. Biotheus
10.8. Crescendo Biologics
10.9. Cue Biopharma
10.10. Eutilex
10.11. F-star Therapeutics
10.12. Genmab
10.13. I-MAB Biopharma
10.14. Lyvgen Biopharma
10.15. Molecular Partners
10.16. OriCell Therapeutics
10.17. Pieris Pharmaceuticals
10.18. Shanghai Henlius Biotech
10.19. Sichuan Baili Pharmaceutical
10.20. SystImmune

簡介目錄圖表

List of Figures

Figure 1-1: Immune Regulation Mechanisms Of Anti-CD137 Monoclonal Antibody
Figure 1-2: Schematic Depiction Of Bidirectional Signaling By CD137-CD137L
Figure 3-1: Dual Co-Stimulatory Trial - Study Initiation & Expected Completion Year
Figure 3-2: RO7227166 - Study Initiation & Expected Completion Year
Figure 3-3: YH004 - Study Initiation & Expected Completion Year
Figure 3-4: GNC-038 - Study Initiation & Expected Completion Year
Figure 3-5: UCD19 CAR T - Study Initiation & Expected Completion Year
Figure 3-6: EU101 - Study Initiation & Expected Completion Year
Figure 3-7: GEN106 - Study initiation & Expected Completion Year
Figure 3-8: HLX35 - Study Initiation & Expected Completion Year
Figure 3-9: Nivolumab & ADG106 - Study Initiation & Expected Completion Year
Figure 3-10: INBRX-105 - Study Initiation & Expected Completion Year
Figure 3-11: NM21-1480 - Study Initiation & Expected Completion Year
Figure 3-12: JAVELIN Medley - Study Initiation & Completion Year
Figure 3-13: AGEN2373 - Study Initiation & Completion Year
Figure 3-14: AVIATOR Study - Study Initiation & Expected Completion Year
Figure 3-15: YH32367 - Study Initiation & Expected Completion Year
Figure 3-16: NM21-140 - Study Initiation & Estimated Completion Year
Figure 3-17: RO7122290 - Study Initiation & Expected Completion Year
Figure 3-18: EU101 - Study Initiation & Completion Year
Figure 4-1: Global - CD137 Targeting Antibodies Clinical Pipeline by Company (Numbers), 2023
Figure 4-2: Global - CD137 Targeting Antibodies Clinical Pipeline by Country (Numbers), 2023
Figure 4-3: Global - CD137 Targeting Antibodies Clinical Pipeline by Indication (Numbers), 2023
Figure 4-4: Global - CD137 Targeting Antibodies Clinical Pipeline by Phase (Numbers), 2023
Figure 4-5: Global - CD137 Targeting Antibodies Clinical Pipeline by Patient Segment (Numbers), 2023
Figure 6-1: ACG106 - Anti-CD137 NEObody
Figure 6-2: ADG206 - Anti-CD137 POWERbody
Figure 6-3: DUObody - Production Process
Figure 6-4: The MATCH Format
Figure 6-5: General Format Of GNC-039
Figure 6-6: General Format Of GNC-035
Figure 6-7: General Format Of GNC-038
Figure 8-1: ATOR-1017 - Mechanism Of Action
Figure 8-2: EU101 - Mode Of Action
Figure 8-3: LVGN6051 - Mechanism Of Action
Figure 8-4: ABL503 - Structure & Mechanism Of Action
Figure 8-5: FS120 - Improving PD-1 & Hemotherapy Responses
Figure 8-6: MP0310 - Mechanism Of Action